Thrombosis

Featured Article

A 64-Year-Old Woman With Colorectal Cancer Presents to ED With Severe Chest Pain

A 64-Year-Old Woman With Colorectal Cancer Presents to ED With Severe Chest Pain

A 64-year-old woman who was recently diagnosed with colorectal cancer is brought to the emergency department with substernal chest pain and shortness of breath.

Latest Features

Latest News

Praxbind Gains Full FDA Approval as Pradaxa Reversal Agent

Praxbind Gains Full FDA Approval as Pradaxa Reversal Agent

Complete reversal was seen within 4 hours in the majority of patients, as measured by ecarin clotting time (ECT 82%) or diluted thrombin time (dTT 99%). In addition, there was a low late of thrombotic events and no new safety events were reported.

Pulmonary Embolism Rule-Out Criteria Can Identify Thromboembolic Events

Pulmonary Embolism Rule-Out Criteria Can Identify Thromboembolic Events

A 3-month risk for a thromboembolic event was assessed using a pulmonary embolism rule-out criteria strategy and compared with a conventional strategy in patients with a low clinical probability of pulmonary embolism.

Pulmonary Embolism With Low Mortality Risk Treated in Outpatient Setting

Pulmonary Embolism With Low Mortality Risk Treated in Outpatient Setting

Acute pulmonary embolism may be managed in an outpatient setting when the patient has a low risk for mortality.

Pulmonary Embolism Risk Prediction in Postpartum Women

Pulmonary Embolism Risk Prediction in Postpartum Women

Certain risk scores may not be reliable for predicting the presence of a pulmonary embolism in pregnant or postpartum women.

Atrial Fibrillation Treated With LAA Occlusion Reduces Thromboembolism Risk

Atrial Fibrillation Treated With LAA Occlusion Reduces Thromboembolism Risk

Surgical left atrial appendage occlusion is associated with a lower risk for thromboembolism-related hospital readmission in older patients with atrial fibrillation who undergo cardiac surgery.

Intermediate-Risk Pulmonary Embolism Treatment With Dabigatran

Intermediate-Risk Pulmonary Embolism Treatment With Dabigatran

Patients diagnosed with an intermediate-risk pulmonary embolism may be able to start oral anticoagulation therapy after completing 72 hours of heparin therapy during hospitalization.

Intermediate-Risk Pulmonary Emboli: Catheter-Directed vs Systemic Thrombolysis

Intermediate-Risk Pulmonary Emboli: Catheter-Directed vs Systemic Thrombolysis

Catheter-directed thrombolysis vs systemic thrombolysis strategies show different risk outcomes for patients with intermediate-risk pulmonary embolism.

Pediatric Pulmonary Embolism: 9 Predictors Identified

Pediatric Pulmonary Embolism: 9 Predictors Identified

Several clinical predictors of pediatric pulmonary embolism have been identified.

Antithrombotic Therapy for Atrial Fibrillation and Valvular Heart Disease: New Joint Consensus Statement

Antithrombotic Therapy for Atrial Fibrillation and Valvular Heart Disease: New Joint Consensus Statement

A new consensus statement provides updated guidelines for antithrombotic therapy in patients with atrial fibrillation associated with valvular heart disease.

FDA Approves Rivaroxaban 10 mg for Recurrent VTE

FDA Approves Rivaroxaban 10 mg for Recurrent VTE

The 10 mg dose of rivaroxaban substantially lowered the risk for recurrent venous thromboembolism.

Sign Up for Free e-Newsletters